Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant
oleh: Maxime Jullien, Marianne Coste‐Burel, Beatrice Clemenceau, Valentin Letailleur, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, Berthe‐Marie Imbert, Jocelyn Ollier, Audrey Grain, Cyrille Touzeau, Philippe Moreau, Marie C Béné, Henri Vié, Patrice Chevallier
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2022-05-01 |
Deskripsi
Abstract The impact of pre‐transplant anti‐severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo‐HSCT) and/or their donors is reported here, showing that the persistence of anti‐SARS‐CoV‐2 antibodies can be detected in almost all patients, whatever the type of vaccine used, and up to 9 months post transplant. Also, an anti‐SARS‐CoV‐2 spike glycoprotein CD3+ T‐cell response could be detected in six (35%) of 17 evaluable patients. This study provides a rationale to consider anti‐SARS‐CoV‐2 vaccination of both recipients and donors before Allo‐HSCT.